The Pharmacy Times® Schizophrenia Resource Center is a comprehensive resource for clinical news and expert insights on treatments for schizophrenia.
July 10th 2025
Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.
Use of Long-Acting Injectable Antipsychotic Medications in Schizophrenia Treatment
April 1st 2025Schizophrenia is a chronic mental illness that significantly affects patients through its symptoms, associated health conditions, and treatment challenges, with long-acting injectable antipsychotics offering potential benefits in improving adherence and reducing relapses.
Read More